EP2279742A3 - Kombinationstherapie zur behandlung von entzündlichen Immunerkrankungen - Google Patents
Kombinationstherapie zur behandlung von entzündlichen Immunerkrankungen Download PDFInfo
- Publication number
- EP2279742A3 EP2279742A3 EP10013063A EP10013063A EP2279742A3 EP 2279742 A3 EP2279742 A3 EP 2279742A3 EP 10013063 A EP10013063 A EP 10013063A EP 10013063 A EP10013063 A EP 10013063A EP 2279742 A3 EP2279742 A3 EP 2279742A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- combinations
- treatment
- immunoinflammatory disorders
- immunoinflammatory
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32767401P | 2001-10-05 | 2001-10-05 | |
EP02800923A EP1448205B1 (de) | 2001-10-05 | 2002-10-04 | Kombinationen für die behandlung von immun-entzündlichen erkrankungen |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02800923.1 Division | 2002-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2279742A2 EP2279742A2 (de) | 2011-02-02 |
EP2279742A3 true EP2279742A3 (de) | 2011-04-20 |
Family
ID=23277540
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10013063A Withdrawn EP2279742A3 (de) | 2001-10-05 | 2002-10-04 | Kombinationstherapie zur behandlung von entzündlichen Immunerkrankungen |
EP02800923A Expired - Lifetime EP1448205B1 (de) | 2001-10-05 | 2002-10-04 | Kombinationen für die behandlung von immun-entzündlichen erkrankungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02800923A Expired - Lifetime EP1448205B1 (de) | 2001-10-05 | 2002-10-04 | Kombinationen für die behandlung von immun-entzündlichen erkrankungen |
Country Status (27)
Country | Link |
---|---|
US (3) | US7253155B2 (de) |
EP (2) | EP2279742A3 (de) |
JP (1) | JP2005508346A (de) |
KR (2) | KR100917082B1 (de) |
CN (1) | CN100400044C (de) |
AR (1) | AR036741A1 (de) |
AT (1) | ATE502642T1 (de) |
AU (1) | AU2002334870B2 (de) |
BR (1) | BR0213100A (de) |
CA (1) | CA2461946C (de) |
DE (1) | DE60239558D1 (de) |
DK (1) | DK1448205T3 (de) |
ES (1) | ES2363334T3 (de) |
HK (1) | HK1076387A1 (de) |
HR (1) | HRP20040388A2 (de) |
IL (1) | IL161267A0 (de) |
IS (1) | IS7202A (de) |
MX (1) | MXPA04003266A (de) |
NO (1) | NO20041386L (de) |
NZ (1) | NZ532310A (de) |
PL (1) | PL370764A1 (de) |
PT (1) | PT1448205E (de) |
RU (1) | RU2322984C2 (de) |
SI (1) | SI1448205T1 (de) |
TW (1) | TWI247605B (de) |
WO (1) | WO2003030823A2 (de) |
ZA (1) | ZA200402955B (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1411938B1 (de) * | 2001-07-02 | 2005-07-06 | Tas, Sinan | Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis |
MXPA04003266A (es) * | 2001-10-05 | 2004-07-08 | Combinatorx Inc | Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios. |
DE602004027014D1 (de) | 2003-03-26 | 2010-06-17 | Synergy Biosystems Ltd | Ttel und synergistischer kombinationen |
US20050112199A1 (en) * | 2003-09-24 | 2005-05-26 | Mahesh Padval | Therapeutic regimens for administering drug combinations |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
WO2005102287A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
US8907153B2 (en) * | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
US20070196452A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Flux-enabling compositions and methods for dermal delivery of drugs |
US7799331B2 (en) * | 2005-08-04 | 2010-09-21 | Taro Pharmaceutical North America, Inc. | Oral suspension of prednisolone acetate |
MX2008014828A (es) * | 2006-05-22 | 2009-02-06 | Combinatorx Inc | Metodos y composiciones para el tratamiento de enfermedades o condiciones asociadas con niveles incrementados de proteina c-reactiva, interleucina-6 o interferon-gamma. |
WO2007150063A2 (en) * | 2006-06-23 | 2007-12-27 | Cargill Incorporated | Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements |
US20100112590A1 (en) | 2007-07-23 | 2010-05-06 | The Chinese University Of Hong Kong | Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment |
EA017966B1 (ru) | 2007-07-23 | 2013-04-30 | Те Чайниз Юниверсити Ов Гонгконг | Диагностика фетальной хромосомной анэуплоидии с использованием геномного секвенирования |
WO2009038708A1 (en) * | 2007-09-19 | 2009-03-26 | Combinatorx, Incorporated | Therapeutic regimens for the treatment of immunoinflammatory disorders |
EP2231129A4 (de) * | 2007-12-17 | 2013-01-30 | Zalicus Inc | Therapeutische schemata zur behandlung von immunentzündlichen erkrankungen |
WO2009144720A1 (en) | 2008-05-27 | 2009-12-03 | Pluristem Ltd. | Methods of treating inflammatory colon diseases |
CN102970974B (zh) * | 2010-05-06 | 2015-03-04 | 卢福研究公司 | 用于治疗皮炎和牛皮癣的去炎松缩酮制剂 |
MD480Z (en) * | 2011-07-07 | 2012-09-30 | Elvira Andon | Method for treating acute ulcerative nonspecific colitis |
US9892230B2 (en) | 2012-03-08 | 2018-02-13 | The Chinese University Of Hong Kong | Size-based analysis of fetal or tumor DNA fraction in plasma |
US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
EA201890929A1 (ru) * | 2015-10-15 | 2018-09-28 | Моше Рогосницки | Низкие дозировки композиций дипиридамола для перорального приема и их использование |
CN111346228B (zh) * | 2018-12-21 | 2022-01-14 | 广州市妇女儿童医疗中心 | 胃肠道疾病的免疫机制及治疗药物 |
CN114432451B (zh) * | 2018-12-21 | 2024-02-09 | 广州市妇女儿童医疗中心 | 胃肠道疾病的免疫机制及治疗药物 |
CN113456618A (zh) * | 2020-03-31 | 2021-10-01 | 天津金耀集团有限公司 | 一种复方双嘧达莫的吸入制剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001047572A2 (en) * | 1999-12-29 | 2001-07-05 | Advanced Cardiovascular Systems, Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
US20010016604A1 (en) * | 1986-12-23 | 2001-08-23 | Yu Ruey J. | Additives enhancing topical actions of therapeutic agents |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US579476A (en) * | 1897-03-23 | Sash-holder | ||
US3031450A (en) | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
AU496759B2 (en) | 1972-12-27 | 1978-10-26 | Schering Aktiengesellschaft | New pregnan-21-oic derivatives |
US4034087A (en) * | 1973-12-17 | 1977-07-05 | The Regents Of The University Of Michigan | Pharmaceutical composition and process of treatment |
US4107306A (en) * | 1973-01-16 | 1978-08-15 | The Regents Of The University Of Michigan | Process for treating proliferative skin disease |
US3934036A (en) * | 1975-01-23 | 1976-01-20 | Kyorin Seiyaku Kabushiki Kaisha | N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent |
FR2470599A1 (fr) | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
BG36086A1 (en) * | 1982-01-19 | 1984-09-14 | Glbov | Method for inducing interferon |
US4387217A (en) * | 1982-04-07 | 1983-06-07 | Basf Wyandotte Corporation | High foaming iodophors |
JPS60174716A (ja) * | 1984-02-21 | 1985-09-09 | Yamanouchi Pharmaceut Co Ltd | パツチ剤 |
US4879119A (en) * | 1984-02-21 | 1989-11-07 | Yamanouchi Pharmaceutical Co., Ltd. | Patch |
US4554271A (en) * | 1984-02-24 | 1985-11-19 | The Upjohn Company | Use of high doses of derivatives of 6α-methylprednisolone for the acute treatment of stroke syndrome |
DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
AU611421B2 (en) | 1987-02-23 | 1991-06-13 | Shiseido Company Ltd. | Percutaneous absorption promoter and dermatologic preparation for external use |
US5668116A (en) * | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
US5242921A (en) * | 1988-04-27 | 1993-09-07 | Yale University | Compositions and methods for treating cutaneous hyperproliferative disorders |
WO1989010122A1 (en) | 1988-04-27 | 1989-11-02 | Yale University | Compositions and methods for treating cutaneous hyperproliferative disorders |
WO1992016226A1 (en) | 1991-03-19 | 1992-10-01 | Smithkline Beecham Corporation | Il-1 inhibitors |
US5270047A (en) * | 1991-11-21 | 1993-12-14 | Kauffman Raymond F | Local delivery of dipyridamole for the treatment of proliferative diseases |
US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
EG20321A (en) * | 1993-07-21 | 1998-10-31 | Otsuka Pharma Co Ltd | Medical material and process for producing the same |
US5428040A (en) | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
US5468729A (en) | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
GB2292079B (en) * | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
DE4430128A1 (de) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
FR2732223B1 (fr) * | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
AU5772196A (en) | 1995-05-19 | 1996-11-29 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
US6265427B1 (en) * | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
US6172066B1 (en) * | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6235706B1 (en) * | 1996-09-18 | 2001-05-22 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
JP2001504457A (ja) | 1996-11-01 | 2001-04-03 | ニトロメド インコーポレーテッド | ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法 |
US5874437A (en) * | 1996-11-01 | 1999-02-23 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US5792476A (en) * | 1996-12-19 | 1998-08-11 | Abigo Medical Ab | Sustained release glucocorticoid pharmaceutical composition |
EP0979096B1 (de) * | 1997-02-15 | 2003-05-14 | Millennium Pharmaceuticals, Inc. | Behandlung von infarkten durch inhibierung von nf-kappab |
US6054487A (en) * | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
KR20000076420A (ko) * | 1997-03-18 | 2000-12-26 | 스타르크, 카르크 | 코르티코스테로이드에 대한 반응성을 조절하기 위한 방법 및 조성물 |
ES2131463B1 (es) * | 1997-04-08 | 2000-03-01 | Lilly Sa | Derivados de ciclopropilglicina con propiedades farmaceuticas. |
ZA984698B (en) | 1997-06-05 | 2000-02-01 | Lilly Co Eli | Methods for treating thombotic disorders. |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
EP1952802A3 (de) | 1997-10-01 | 2009-06-17 | Novadel Pharma Inc. | Oraler, polarer und nicht-polarer Spray bzw. Kapsel |
US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
WO1999062537A1 (en) * | 1998-06-04 | 1999-12-09 | The Rockefeller University | Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins |
CN1246335A (zh) * | 1998-08-28 | 2000-03-08 | 冀聪韬 | 一种用于治疗皮肤病药物的制作方法 |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6602521B1 (en) * | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
US6677326B2 (en) * | 1999-03-15 | 2004-01-13 | Arakis, Ltd. | Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
WO2001002497A1 (en) | 1999-06-30 | 2001-01-11 | Beltran, German Cuevas | Process and product for rendering a substance flame resistant |
US7358056B1 (en) * | 1999-08-30 | 2008-04-15 | Signal Pharmaceuticals | Methods for modulating signal transduction mediated by TGF-β and related proteins |
US6585995B1 (en) * | 1999-09-21 | 2003-07-01 | Hanson Stephen R | Methods and compositions for treating platelet-related disorders |
EP1093814A1 (de) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Verwendung von Dipyridamole oder Mopidamol zur Herstellung eines Medikaments für die Behandlung und Vorbeugung von fibrinabhängigen Mikrozirkulationstörungen |
EP1233768A1 (de) | 1999-11-15 | 2002-08-28 | Smithkline Beecham | Carvedilolmethansulphonat |
US6363471B1 (en) * | 2000-01-03 | 2002-03-26 | Advanced Micro Devices, Inc. | Mechanism for handling 16-bit addressing in a processor |
WO2001054679A2 (en) | 2000-01-27 | 2001-08-02 | Children's Hospital Research Foundation | Transdermal composition containing an anesthetic and a vasodilator agent |
DE10012555A1 (de) * | 2000-03-15 | 2001-09-20 | Merck Patent Gmbh | Glucocorticoide in einer Modified Release-Formulierung |
AU2001265111A1 (en) * | 2000-05-30 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
AU2000270300A1 (en) | 2000-09-13 | 2002-03-26 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
IL140537A0 (en) * | 2000-12-25 | 2002-02-10 | Hadasit Med Res Service | Educated nk t cells and their uses in the treatment of immune-related disorders |
CA2439691A1 (en) * | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
US6759058B1 (en) | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
US6960357B2 (en) | 2001-05-25 | 2005-11-01 | Mistral Pharma Inc. | Chemical delivery device |
GB0119848D0 (en) | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
MXPA04003266A (es) | 2001-10-05 | 2004-07-08 | Combinatorx Inc | Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios. |
US20030129250A1 (en) | 2001-11-20 | 2003-07-10 | Advanced Inhalation Research Inc. | Particulate compositions for improving solubility of poorly soluble agents |
US6877326B2 (en) * | 2002-03-20 | 2005-04-12 | Lg Electronics Inc. | Operation control apparatus and method of linear compressor |
US20040180812A1 (en) * | 2002-12-13 | 2004-09-16 | Technology Center | Methods of treating and preventing proliferative disease |
JP2006515320A (ja) | 2002-12-31 | 2006-05-25 | ラリー エル オーグスバーガー | 活性クッション性成分を含有する医薬品剤形の製造方法 |
CN1747734A (zh) | 2003-02-07 | 2006-03-15 | 贝林格尔·英格海姆国际有限公司 | 潘生丁或单哌潘生丁在治疗和预防mmp-9-依赖性疾病中的用途 |
US20050058688A1 (en) * | 2003-02-22 | 2005-03-17 | Lars Boerger | Device for the treatment and prevention of disease, and methods related thereto |
US9149440B2 (en) | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
CA2640484A1 (en) | 2006-01-26 | 2007-08-09 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith |
ES2533563T5 (es) | 2006-01-27 | 2018-07-24 | Adare Pharmaceuticals, Inc. | Sistemas de suministro de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos |
KR20080112270A (ko) | 2006-03-07 | 2008-12-24 | 콤비네이토릭스, 인코포레이티드 | 면역염증성 질환의 치료를 위한 조성물 및 치료방법 |
-
2002
- 2002-10-04 MX MXPA04003266A patent/MXPA04003266A/es unknown
- 2002-10-04 NZ NZ532310A patent/NZ532310A/en not_active IP Right Cessation
- 2002-10-04 KR KR1020077019833A patent/KR100917082B1/ko not_active IP Right Cessation
- 2002-10-04 SI SI200230946T patent/SI1448205T1/sl unknown
- 2002-10-04 BR BR0213100-5A patent/BR0213100A/pt not_active IP Right Cessation
- 2002-10-04 EP EP10013063A patent/EP2279742A3/de not_active Withdrawn
- 2002-10-04 PL PL02370764A patent/PL370764A1/xx not_active Application Discontinuation
- 2002-10-04 CA CA002461946A patent/CA2461946C/en not_active Expired - Fee Related
- 2002-10-04 AU AU2002334870A patent/AU2002334870B2/en not_active Ceased
- 2002-10-04 AT AT02800923T patent/ATE502642T1/de active
- 2002-10-04 IL IL16126702A patent/IL161267A0/xx unknown
- 2002-10-04 DE DE60239558T patent/DE60239558D1/de not_active Expired - Lifetime
- 2002-10-04 KR KR1020047005050A patent/KR100824491B1/ko not_active IP Right Cessation
- 2002-10-04 ES ES02800923T patent/ES2363334T3/es not_active Expired - Lifetime
- 2002-10-04 AR ARP020103758A patent/AR036741A1/es unknown
- 2002-10-04 US US10/264,991 patent/US7253155B2/en not_active Expired - Fee Related
- 2002-10-04 JP JP2003533857A patent/JP2005508346A/ja active Pending
- 2002-10-04 EP EP02800923A patent/EP1448205B1/de not_active Expired - Lifetime
- 2002-10-04 DK DK02800923.1T patent/DK1448205T3/da active
- 2002-10-04 RU RU2004113551/14A patent/RU2322984C2/ru not_active IP Right Cessation
- 2002-10-04 PT PT02800923T patent/PT1448205E/pt unknown
- 2002-10-04 CN CNB028239962A patent/CN100400044C/zh not_active Expired - Fee Related
- 2002-10-04 WO PCT/US2002/031866 patent/WO2003030823A2/en active Application Filing
- 2002-10-07 TW TW091123107A patent/TWI247605B/zh not_active IP Right Cessation
-
2004
- 2004-03-31 IS IS7202A patent/IS7202A/is unknown
- 2004-04-02 NO NO20041386A patent/NO20041386L/no not_active Application Discontinuation
- 2004-04-19 ZA ZA200402955A patent/ZA200402955B/en unknown
- 2004-05-04 HR HR20040388A patent/HRP20040388A2/hr not_active Application Discontinuation
-
2005
- 2005-09-23 HK HK05108422.6A patent/HK1076387A1/xx not_active IP Right Cessation
-
2006
- 2006-02-15 US US11/354,552 patent/US7915265B2/en not_active Expired - Fee Related
-
2011
- 2011-03-15 US US13/048,587 patent/US20110223621A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010016604A1 (en) * | 1986-12-23 | 2001-08-23 | Yu Ruey J. | Additives enhancing topical actions of therapeutic agents |
WO2001047572A2 (en) * | 1999-12-29 | 2001-07-05 | Advanced Cardiovascular Systems, Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2279742A3 (de) | Kombinationstherapie zur behandlung von entzündlichen Immunerkrankungen | |
WO2005037203A3 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
WO2004073614A3 (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
WO2005027839A3 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
WO2004019863A3 (en) | Combination therapy for treatment of fibrotic disorders | |
DE60035870D1 (de) | Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung | |
ATE457166T1 (de) | Orale zusammensetzungen zur behandlung von diabetes | |
HUP0301729A2 (hu) | Gyógyszer szívelégtelenség megelżzésére és kezelésére | |
HUP0303917A2 (hu) | Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére | |
WO2002053106A3 (en) | Autoantigen composition | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
WO2003049804A3 (en) | Treatment of genitourinary tract disorders | |
WO2004030618A3 (en) | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | |
MXPA03010406A (es) | Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd. | |
HK1081862A1 (en) | Synergistic combination comprising roflumilast and (r,r)-formoterol | |
WO2002062300A3 (en) | Cholesterol-lowering agents as treatment for psychological and cognitive disorders | |
WO2003092701A3 (en) | Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders | |
GB0129962D0 (en) | Method of treatment | |
WO2003045322A3 (en) | Method for treating and preventing pancreatitis | |
AU2001276323A1 (en) | Use of n-oleoylethanolamine for treating psoriasis | |
EP1512413A3 (de) | Pharmazeutische Mischung gegen Krebs, die ein 4-Chinazolinamin in Kombination mit einem anderen antineoplastischen Wirkstoff enthält | |
BRPI0407421A (pt) | Terapia combinada para o tratamento de distúrbios imunoinflamatórios | |
UA30749A (uk) | Спосіб комплексної стимулотерапії тяжких форм мовних розладів | |
UA32314A (uk) | Спосіб лікування некротичного панкреатиту | |
AU2003283145A1 (en) | Apparatus for stimulating blood vessels and treating and preventing vascular disorders, and unit comprising such an apparatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20101001 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1448205 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BORISY, ALEXIS Inventor name: KEITH, CURTIS |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130403 |